Norrsken22

Norrsken22 is a growth-stage African venture firm backed by a high-profile group of European unicorn founders (Skype, Klarna, Spotify, iZettle alumni), deploying $5M-$25M cheques at Series A, Series B, and Series C into companies addressing the African mass market, including medical devices, health IT, and digital health. The firm combines patient growth capital with operational expertise from founders who have built billion-dollar companies in adjacent emerging markets. For founders, Norrsken22 is best positioned as a regional growth lead that can anchor Series A and B rounds for African digital health platforms with multi-country traction. The right founder profile is an African operator or ambitious diaspora team building a digital health, telemedicine, medical device, or health IT platform with revenue-stage traction across Nigeria, Kenya, South Africa, Egypt, or other large African markets, and a clear plan to address the mass market rather than premium niche segments. Founders running early-stage pre-revenue plays, capital-intensive hospital networks, or single-country boutique propositions should not approach. The cleanest entry path is via a Norrsken22 portfolio CEO, the founder network of the European LP base, or warm introductions from earlier-stage African funds (FirstCheck, EchoVC, Enza, HealthCap) that frequently flow deals upward. In the pitch, lead with mass-market unit economics in local currency, multi-country traction signals, regulatory navigation in target markets, and a credible plan for capital efficiency and Series B follow-on. Caveats: Norrsken22 prices for growth-stage discipline, cycle times are institutional, and founders should be realistic about FX, exit, and follow-on dynamics across African markets. AI focus is a stated interest but the core thesis is mass-market scalability, so AI claims will be evaluated commercially.